Generating Innovation with Japan: Toronto HealthTech€¦ · Otsuka Holdings Co., Ltd. (Otsuka HD ... Product Portfolio -Oncology Pipeline ... (co-promotion) 2012 FAES FARMA Bilanoa*
Post on 09-Oct-2020
6 Views
Preview:
Transcript
Generating Innovation with Japan:
Toronto HealthTech
Taiho Pharmaceuticals
Robert Tam, Director, Market Access
February 20, 2020
1
1
Taiho Corporate Philosophy
2
2
Taiho at a Glance
● Established June, 1963
● Head office Tokyo
● President & Representative Director Masayuki Kobayashi
● Employees 2,380
● Net sales ¥124.9B (US$1.12B)
● R&D expenditures 27.3% of sales2018 Fiscal year (2018 Jan- 2018 Dec) results;
1USD = 111.43JPY
Employees
n=2,380
Discovery
Clinical・MA
CMC
Production
Drug Sales
CHC
QA
OthersOncology
73.9%Urology 1.1%
Other Drugs 1.8%
Others(Bulk, Royalty)
3.7%
OTC 10.1%
(as of January 2019)
Net Sales
¥ 124.9 B
Dermatology / Allergy
9.4%
3
3
Offices and Facilities
Tsukuba ・ Target identification・ Lead optimization
Tokushima・ Pre-clinical studies・ CMC development
Saitama (API)U.S. InspectionEuropean authorities Inspection
Kitajima (Products)U.S. InspectionEuropean authorities InspectionOSDrC Tec
Drug Discovery Drug Development Manufacturing Sales & Marketing
● Head Office/Tokyo
・ Headquarter functions・ Clinical development・ QA・ Medical affairs・ Marketing
● Branch Offices: 15
Pharmaceutical value chain
Tokushima (Products)U.S. InspectionEuropean authorities Inspection
Inuyama (API)
Okayama (OTC)
● Research Institute: 2 ● Plants: 5
・ Ethical drug: 15・ Consumer: 7
4
4
Taiho Subsidiary Companies
Taiho Pharma Singapore Pte., Ltd.
Sales
Taiho Pharmaceuticalof Beijing Co., Ltd.Promotion/Clinical
Taiho Pharma Europe, Ltd.Clinical
Taiho Oncology, Inc.Sales/Clinical
Taiho Pharma Canada, Inc.Sales
Taiho Ventures LLC.Venture Capital
Okayama -TaihoPharmaceutical Co., Ltd.
Research / Clinical /Production / Sales
Taiho Pharmaceutical Co., Ltd.
Global Headquarters
Taiho Innovations LLC.Venture Capital
5
5
● Otsuka Group Profile
189 companies (162 subsidiaries and 26 affiliates , plus 1 company (Otsuka Holdings itself))About 47,000 employees
Global network: JP, Asia, MEA, Oceania, EU, NA, LA
Taiho is a wholly owned subsidiary of Otsuka HD.Otsuka HD also holds a 100% share of 6 other companies.
● Structure of Group Capital
1st section of the Tokyo Stock Exchange.
(as of December 31, 2018)
Otsuka
Chemical
・Functional chemicals
・Fine chemicals
Otsuka
Pharmaceutical
・Pharmaceutical Business
・NutraceuticalBusiness
Otsuka
Pharmaceutical Factory
・Pharmaceutical Business
・Nutraceutical Business
Taiho
Pharmaceutical
・Pharmaceutical
Business
・Nutraceutical
Business
Otsuka
Warehouse
・Distribution
Otsuka
Medical Devices
・Medical devices
Otsuka
Foods
・ConsumerProducts
Business
Nutraceuticals = nutrition + pharmaceuticals
(as of December 31, 2018 )
Otsuka Holdings Co., Ltd.(Otsuka HD)
Overview of Otsuka Group
6…
North America
7
7
Our Business Focus
Gastrointestinal Diseases(Gastrointestinal tract and related organs)
- Cancer & Supportive care
- Unmet medical needs
Products: Lonsurf, Abraxane, Aloxi, TS-1, Uzel
Dermatology and Otolaryngology(Skin, Nose, Ear, and related organs)
- Allergy
- Psoriasis & Dermatitis
Products: Bilanoa, Tremfya, Methaderm, IPD
Pulmonary Diseases(Lung, Bronchi, and related organs)
- Cancer & Supportive care
- Inflammatory Diseases
Products: Abraxane, Aloxi, TS-1, Keytruda
Other Diseases(Mammary gland, Bladder and other organs)
- Cancer & Supportive care
- Urination Dysfunctions- Rare Cancers & diseases
Products: Abraxane, Aloxi, TS-1, Zolinza, Yondelis
9
9
Product Portfolio - Oncology Pipeline -
Pre-clinical Phase 1 Phase 2 Phase 3
TAS-118Antimetabolite (TS-1/Leukovorin)
GastricJPN, Asia
TAS-115c-MET/VEGFR inhibitorProstateJPN
TAS-114dUTPase/DPD inhibitorNSCLCJPN, US, CAN, EU
TAS-116HSP90 inhibitorGISTJPN, US, CAN, EU
TAS-120FGFR inhibitorIntrahepatic Bile DuctJPN, US, CAN, EU
Pro-NETUNK1RAChemotherapy-induced Nausea & Vomiting
JPN In-licensed from Helsinn
ET-743DNA minor groove binderOvarianJPNIn-licensed from PharmaMar
TAS-117Allosteric Akt inhibitorSolid TumorJPN
TAS4464NAE inhibitorSolid Tumor & Hematological Cancer
JPN, US, EU
TAS3681Novel AR antagonistProstateUS, EU
TAS0728Her2 inhibitorSolid TumorUS, EU
TAS0313Peptide VaccineSolid TumorJPN
TAS6417/CLN-081
EGFR inhibitorNSCLCGlobalOut-licensed to Cullinan Pearl
RET inhibitorRET inhibitor
Co-development with Helsinn
AB928A2AR/A2BR Antagonist
In-licensed from Arcus
Molecular targeting Supportive careCytotoxic
・・・
And other projects
KRAS programsKRAS inhibitors
Research Collaboration and License Agreement with MSD
10
10
Major Collaborations
2016-2019MSD
KEYTRUDA*(co-promotion)
2005 Teva(formerly Cima)
E-fen (OVF)
2009 PharmaMar Yondelis2017 ARCUS(option agreement)
2017JANSSEN
Tremfya*(co-promotion)
2012FAES FARMA
Bilanoa*
2004Helsinn
Aloxi
MIRATI 2003(formerly MethylGene)
Mocetinostat
2005Celgene(formerly Abraxis)
Abraxane
2015 Bilanoa
(co-marketing)MEIJI SEIKA PHAMA
2011TS-1
NORDIC
2015LonsurfSERVIER
2016LonsurfJEIL
2017LonsurfTTY
1995ZosynPfizer(formerly Wyeth)
2000ZosynTaisho Toyama*
1995 2005 2010 2015
In-license
Out-license
OncologyGeneral
* Domestic
2011 MSD Zolinza* 2018 AB928*
2019TAS6417CULLINAN PEARL
2020KRAS programsMSD
2019 Acquisition ASTEXOtsuka
11
11
Major Collaborations
2016-2019MSD
KEYTRUDA*(co-promotion)
2005 Teva(formerly Cima)
E-fen (OVF)
2009 PharmaMar Yondelis2017 ARCUS(option agreement)
2017JANSSEN
Tremfya*(co-promotion)
2012FAES FARMA
Bilanoa*
2004Helsinn
Aloxi
MIRATI 2003(formerly MethylGene)
Mocetinostat
2005Celgene(formerly Abraxis)
Abraxane
2015 Bilanoa
(co-marketing)MEIJI SEIKA PHAMA
2011TS-1
NORDIC
2015LonsurfSERVIER
2016LonsurfJEIL
2017LonsurfTTY
1995ZosynPfizer(formerly Wyeth)
2000ZosynTaisho Toyama*
1995 2005 2010 2015
In-license
Out-license
OncologyGeneral
* Domestic
2011 MSD Zolinza* 2018 AB928*
2019TAS6417CULLINANPEARL
2020KRAS programsMSD
2019 Acquisition ASTEXOtsuka
12
New Business Development…
13
Taiho Ventures Fact Sheet
Inception 2016
Business Investment into Global Biotech Ventures
Office Menlo Park, CA
Investment Pool $300M
Report Line Global Chief Corporate Officer
Goal of Investment Strategic Benefits > Financial Returns
Strategic Benefits:
Invest in promising biotech ventures with potential alliance opportunities in the
near future
Access to new biology candidates beyond Internal R&D
Option Investment including establishing Build to Buy opportunities
Create spin-out companies using Taiho pipeline programs
Seeking investments in early stage preclinical oncology as well as platform technology companies for our
core therapeutic areas. We will review the wide variety of modalities (both biologics and small molecules)
and opportunities mainly in North America and Europe. We will also consider the option-type of investments
and spin-outs, in addition to pure equity investments.
14
Investment Sectors:
Drug Discovery (1st-in-class or New biology based approach)
Innovative Platform Technologies for Drug Discovery
Spin-out Opportunities from Taiho Pipelines
Medical Device/Diagnostics/Digital Health (opportunistic)
Therapeutic areas:
Oncology
Non-oncology (Immunology/Allergy/Bone/Muscle/Orphan)
Modality:
Small molecules
Biologics/Oncolytic virus
Gene/Cell Therapy
Stage:
Research to Pre-IND
IND to PoC (opportunistic)
Region:
Mainly NA, EU and Japan
Taiho Ventures Investment Criteria
15
Examples of Potential Investment Arena:
Immune checkpoint pathway
CAR-T/TCR-T
2nd generation of T-cell engager
Post PD-1 therapy (tumor microenvironment)
Cytokine
Microbiome
Next generation oncolytic virus
Intracellular undruggable targets
Protein degrader
DNA damage response
Chromatin remodeling
RNA epigenetics/modulator/splicing/editing
Cancer resistance
AI based drug discovery
Senescence
Autophagy
Taiho Ventures Interest in Oncology
and Portfolio
Actively seeking new science in oncology!
16
Taiho Ventures Portfolio
17
Research Collaboration with X-Chem
Initiated by Taiho Ventures
18
Innovative R&D Collaboration with Arcus
Biosciences (a Taiho Ventures portfolio)
Innovative deal structure: Term Sheet negotiated by Taiho Ventures
Opted in AB928 (A2aR and A2bR dual antagonist) in 2018
19
Spin-out activities using Taiho
molecules
CONFIDENTIAL
20
20
Please visit our web sites:
⇒www.taiho.co.jp/en/
⇒www.taihooncology.com
→www.taihopharma.ca/
Thank You !
top related